Compare HLT & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLT | TAK |
|---|---|---|
| Founded | 1919 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5B | 56.6B |
| IPO Year | 2013 | N/A |
| Metric | HLT | TAK |
|---|---|---|
| Price | $317.36 | $18.67 |
| Analyst Decision | Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $308.27 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.9M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | 0.20% | ★ 2.88% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.12 | N/A |
| Revenue | ★ $12,039,000,000.00 | N/A |
| Revenue This Year | $9.74 | $0.38 |
| Revenue Next Year | $8.36 | $1.02 |
| P/E Ratio | $49.38 | ★ $41.25 |
| Revenue Growth | ★ 7.74 | N/A |
| 52 Week Low | $201.15 | $12.99 |
| 52 Week High | $333.86 | $18.90 |
| Indicator | HLT | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 61.09 | 58.38 |
| Support Level | $288.25 | $17.65 |
| Resistance Level | $319.61 | N/A |
| Average True Range (ATR) | 6.52 | 0.28 |
| MACD | 1.81 | 0.03 |
| Stochastic Oscillator | 92.54 | 81.61 |
Hilton Worldwide Holdings operates 1.35 million rooms across its 25 brands, serving the premium economy through luxury segments. Hampton and Hilton are the two largest brands, representing 27% and 18%, respectively, of the company's total rooms, as of Dec. 31, 2025. Recent brands launched over the past few years include Home2, Curio, Canopy, Spark, Tru, Tempo, LivSmart, and Outset. Additionally, there is a partnership with Small Luxury Hotels of the World and acquisitions of NoMad and Graduate Hotels. Managed and franchised hotels represent the vast majority of adjusted EBITDA, predominantly from the Americas.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.